Mito-TRFS

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Mito-TRFS  纯度: 95.75%

Mito-TRFS 是首个off-on 探针,可用于活细胞中线粒体硫氧还蛋白还原酶 (TrxR2) 的呈像。

Mito-TRFS

Mito-TRFS Chemical Structure

CAS No. : 1859102-62-7

规格 价格 是否有货 数量
1 mg ¥2400 In-stock
5 mg ¥7200 In-stock
10 mg ¥11500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Mito-TRFS 相关产品

相关化合物库:

  • Bioactive Compound Library Plus

生物活性

Mito-TRFS, the first off-on probe, is used to image the mitochondrial thioredoxin reductase (TrxR2) in live cells[1].

体外研究
(In Vitro)

Mito-TRFS (10 μM) has the maximal absorption at ~375 nm in TE buffer (50 mM Tris-HCl and 1 mM EDTA, pH 7.4) at 37 °C[1].
Mito-TRFS itself has a strong emission at ~480 nm when excited at 375 nm in TE buffer (φ=0.34), but has weak emission when excited at 438 nm[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence[1].

Cell Line: HeLa cells.
Concentration: 1 μM.
Incubation Time: 2 h.
Result: Mito-TRFS is localized predominantly in the mitochondria of live cells.

分子量

820.70

Formula

C38H34IN2O5PS2

CAS 号

1859102-62-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献
  • [1]. Yaping Liu, et al. A small molecule probe reveals declined mitochondrial thioredoxin reductase activity in a Parkinson’s disease model. Chem Commun (Camb). 2016 Feb 7;52(11):2296-9.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Mito-LND(Synonyms: Mito-Lonidamine)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Mito-LND (Synonyms: Mito-Lonidamine) 纯度: 97.00%

Mito-LND (Mito-Lonidamine) 是一种具有口服活性的且靶向线粒体的氧化磷酸化 (oxidative phosphorylation (OXPHOS)) 抑制剂。Mito-LND 抑制线粒体生物能,刺激活性氧 (reactive oxygen species) 的形成,并诱导肺癌细胞自噬细胞死亡。

Mito-LND(Synonyms: Mito-Lonidamine)

Mito-LND Chemical Structure

CAS No. : 2361564-49-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥5110 In-stock
5 mg ¥3500 In-stock
10 mg ¥5800 In-stock
25 mg ¥11000 In-stock
50 mg ¥17000 In-stock
100 mg ¥25000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Mito-LND 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Oxygen Sensing Compound Library
  • Ferroptosis Compound Library
  • Pyroptosis Compound Library
  • Orally Active Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Mitochondria-Targeted Compound Library
  • Glucose Metabolism Compound Library

生物活性

Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells[1].

体外研究
(In Vitro)

Mito-LND blocks lung cancer growth, migration, and invasion. Mito-LND inhibits cell growth of H2030BrM3 and A549 cells with IC50 values of 0.74 µM and 0.69 µM, respectively[1].
Mito-LND inhibits mitochondrial complex I and II activities with IC50 values of 1.2 µM and 2.4 µM, respectively in H2030BrM3 cells[1].
Mito-LND (1 µM) increases ROS generation in H2030BrM3 lung cancer cells. Mito-LND potently induces mitochondrial ROS generation in H2030BrM3 lung cancer cells[1].
Mito-LND (2 µM) decreases the levels of phosphorylated AKT. Mito-LND also decreases the phosphorylation of P70S6K and other energy-sensing proteins in both the parental and metastatic lung cancer cell lines, indicating that Mito-LND specifically downregulates mTOR signaling[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Mito-LND (7.5 µmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) treatment markedly enhanced potency against both lung cancer progression and metastasis[1].
Mito-LND also decreases the rate of growth of A549 tumor xenografts[1].
Mito-LND treatment shows a marked decrease in lung cancer brain metastasis in NOD/SCID mice bearing H2030BrM3 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic nude mice (5 weeks) injected with H2030BrM3 cells[1]
Dosage: 7.5 µmol/kg
Administration: Oral gavage; 5 days per week; for 3 consecutive weeks
Result: Significantly decreased tumor progression.

分子量

801.62

Formula

C43H45BrCl2N3OP

CAS 号

2361564-49-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 50 mg/mL (62.37 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2475 mL 6.2374 mL 12.4747 mL
5 mM 0.2495 mL 1.2475 mL 2.4949 mL
10 mM 0.1247 mL 0.6237 mL 1.2475 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.12 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务